Wealth Alliance Advisory Group LLC Raises Holdings in Pfizer Inc. (NYSE:PFE)

Wealth Alliance Advisory Group LLC lifted its holdings in Pfizer Inc. (NYSE:PFE) by 90.0% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 32,735 shares of the biopharmaceutical company’s stock after buying an additional 15,507 shares during the quarter. Wealth Alliance Advisory Group LLC’s holdings in Pfizer were worth $947,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Olistico Wealth LLC acquired a new position in shares of Pfizer during the 2nd quarter worth $25,000. MFA Wealth Advisors LLC purchased a new position in Pfizer in the second quarter valued at about $29,000. Quarry LP acquired a new stake in shares of Pfizer during the 2nd quarter valued at approximately $31,000. Trivant Custom Portfolio Group LLC grew its holdings in shares of Pfizer by 100.0% in the 1st quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 600 shares during the period. Finally, Financial Connections Group Inc. purchased a new position in Pfizer in the 2nd quarter valued at approximately $34,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Wall Street Analyst Weigh In

PFE has been the topic of several research reports. Wells Fargo & Company upped their target price on Pfizer from $28.00 to $30.00 and gave the company an “equal weight” rating in a report on Wednesday, July 31st. Daiwa Capital Markets raised shares of Pfizer from a “neutral” rating to an “outperform” rating and increased their price objective for the company from $28.00 to $34.00 in a research note on Wednesday, August 7th. Daiwa America upgraded shares of Pfizer from a “moderate buy” rating to a “strong-buy” rating in a report on Wednesday, August 7th. StockNews.com raised shares of Pfizer from a “hold” rating to a “buy” rating in a report on Wednesday, October 9th. Finally, Barclays raised their price objective on shares of Pfizer from $30.00 to $32.00 and gave the stock an “equal weight” rating in a research note on Wednesday, July 31st. Seven investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $33.91.

Pfizer Trading Down 0.2 %

Shares of Pfizer stock opened at $29.22 on Friday. Pfizer Inc. has a fifty-two week low of $25.20 and a fifty-two week high of $31.54. The business’s fifty day moving average is $29.07 and its two-hundred day moving average is $28.44. The company has a quick ratio of 0.60, a current ratio of 0.86 and a debt-to-equity ratio of 0.65. The firm has a market cap of $165.58 billion, a PE ratio of -487.00, a P/E/G ratio of 1.02 and a beta of 0.67.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.46 by $0.14. Pfizer had a positive return on equity of 8.42% and a negative net margin of 4.66%. The firm had revenue of $13.28 billion for the quarter, compared to analyst estimates of $12.96 billion. During the same period last year, the company earned $0.67 EPS. The firm’s quarterly revenue was up 2.1% on a year-over-year basis. Analysts anticipate that Pfizer Inc. will post 2.66 earnings per share for the current year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, December 2nd. Investors of record on Friday, November 8th will be given a dividend of $0.42 per share. This represents a $1.68 annualized dividend and a yield of 5.75%. The ex-dividend date is Friday, November 8th. Pfizer’s dividend payout ratio (DPR) is -2,800.00%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.